A Randomized Comparison of Transobturator Tape With the Plication of Urethral Ligaments in the Treatment of Stress Urinary Incontinence
Launched by ALEV ESERCAN · Jan 22, 2024
Trial Information
Current as of July 15, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical procedures to help women who experience stress urinary incontinence, which is a condition where urine leaks out during activities like coughing, sneezing, or exercising. The researchers want to find out which surgery works better: the transobturator tape (TOT) operation or the urethral ligament plication operation. They will also look at which procedure has fewer complications or risks.
To participate, women must be at least 18 years old and have symptoms of stress urinary incontinence. However, women who are pregnant, have had certain previous surgeries, or have other specific medical conditions may not be eligible. Participants will be followed for up to one year after their surgery, with check-ins at about 5 days, 2.5 months, 6 months, and 1 year to see how they are doing and if they have experienced any complications. This trial aims to help improve treatment options for women dealing with this common issue.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Being 18 years or older
- • 2. Presence of stress urinary incontinence symptoms
- • 3. Agreeing to have surgery
- Exclusion Criteria:
- • 1. Pregnancy
- • 2. Being under 18 years of age
- • 3. Suspicion of malignancy
- • 4. History of previous mid-urethral sling or urinary incontinence surgery
- • 5. Being diagnosed with intrinsic sphincter (urethral) insufficiency
- • 6. Urinary incontinence due to neurological bladder
About Alev Esercan
Alev Esercan is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and robust trial management. With a focus on therapeutic areas that address unmet medical needs, Alev Esercan leverages a collaborative approach to foster partnerships with healthcare professionals, regulatory bodies, and research institutions. The organization prioritizes ethical standards and patient safety, ensuring that all clinical trials are conducted with the highest level of integrity and compliance. Through rigorous data analysis and a commitment to scientific excellence, Alev Esercan aims to contribute significantly to the development of effective therapies and enhance the overall landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
şanlıurfa, , Turkey
Patients applied
Trial Officials
Peter Emanuel Petros, Prof.
Study Director
retired
Alev Esercan, MD
Principal Investigator
Sanliurfa Education and Research Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported